BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
Botulinum Antitoxin Patient Registry for the Evaluation of Safety and Clinical Outcomes of Pediatric and Adult Patients Following BAT Treatment for Confirmed or Suspected Exposure to Botulinum Toxin.
Sponsor: Biomedical Advanced Research and Development Authority
This observational or N/A phase trial investigates Botulism and is currently completed. Biomedical Advanced Research and Development Authority leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Apr 2024 — Jul 2024 [monthly]
Completed
-
Mar 2021 — Apr 2024 [monthly]
Completed
-
Jan 2021 — Mar 2021 [monthly]
Completed
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Completed NA
Status: Enrolling By Invitation → Completed
-
Jun 2017 — Feb 2018 [monthly]
Enrolling By Invitation NA
-
Jan 2017 — Jun 2017 [monthly]
Enrolling By Invitation NA
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Biomedical Advanced Research and Development Authority
- Centers for Disease Control and Prevention
- Emergent BioSolutions
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.